Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Zentalis Pharmaceuticals Inc (ZNTL)

Zentalis Pharmaceuticals Inc (ZNTL)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 835,199
  • Shares Outstanding, K 70,960
  • Annual Sales, $ 0 K
  • Annual Income, $ -292,190 K
  • 60-Month Beta 1.73
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 2.10
Trade ZNTL with:

Options Overview Details

View History
  • Implied Volatility 92.22% ( -3.75%)
  • Historical Volatility 74.05%
  • IV Percentile 80%
  • IV Rank 27.09%
  • IV High 173.09% on 05/25/23
  • IV Low 62.17% on 06/23/23
  • Put/Call Vol Ratio 1.67
  • Today's Volume 8
  • Volume Avg (30-Day) 23
  • Put/Call OI Ratio 0.03
  • Today's Open Interest 742
  • Open Int (30-Day) 1,006

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 10 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/24
See More
  • Average Estimate -0.85
  • Number of Estimates 7
  • High Estimate -0.41
  • Low Estimate -0.96
  • Prior Year -1.07
  • Growth Rate Est. (year over year) +20.56%

Price Performance

See More
Period Period Low Period High Performance
1-Month
10.39 +5.73%
on 04/25/24
16.26 -32.46%
on 04/01/24
-2.60 (-19.11%)
since 03/25/24
3-Month
10.39 +5.73%
on 04/25/24
18.07 -39.21%
on 02/28/24
-2.09 (-15.95%)
since 01/25/24
52-Week
9.56 +14.91%
on 11/08/23
31.46 -65.08%
on 05/30/23
-10.81 (-49.59%)
since 04/25/23

Most Recent Stories

More News
Why Shares of Zentalis Pharmaceuticals Dropped This Week

A rash of insider selling meant the stock gave back some of its gains from last week.

RHHBY : 30.0200 (-1.70%)
ZNTL : 10.98 (-6.67%)
Newman Ferrara LLP Announces Corporate Governance Investigations of Zentalis Pharmaceuticals, Inc. (ZNTL)

Newman Ferrara LLP announced today that the firm is conducting investigations on behalf of shareholders of Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) (“Zentalis” or the “Company”). The investigations...

ZNTL : 10.98 (-6.67%)
Moore Kuehn, PLLC Encourages Investors of Zentalis Pharmaceuticals, Inc. to Contact Law Firm

/PRNewswire/ -- Moore Kuehn, PLLC, a securities law firm located on Wall Street, is investigating whether certain officers and directors of Zentalis...

ZNTL : 10.98 (-6.67%)
Can Zentalis Pharmaceuticals, Inc. (ZNTL) Climb 170% to Reach the Level Wall Street Analysts Expect?

The average of price targets set by Wall Street analysts indicates a potential upside of 170.4% in Zentalis Pharmaceuticals, Inc. (ZNTL). While the effectiveness of this highly sought-after metric is questionable,...

ZNTL : 10.98 (-6.67%)
Zentalis Pharmaceuticals Reports Second Quarter 2022 Financial Results and Operational Update

Strengthened leadership team with the appointment of additional industry veterans, including CEO Dr. Kimberly Blackwell and Chairman Dave Johnson Received...

ZNTL : 10.98 (-6.67%)
Zentalis Pharmaceuticals to Participate in the Wedbush PacGrow Healthcare Conference

NEW YORK and SAN DIEGO, Aug. 03, 2022 (GLOBE NEWSWIRE) -- Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company...

ZNTL : 10.98 (-6.67%)
Zentalis Pharmaceuticals, Inc. Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

NEW YORK and SAN DIEGO, Aug. 01, 2022 (GLOBE NEWSWIRE) -- Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company...

ZNTL : 10.98 (-6.67%)
Zentalis Pharmaceuticals Appoints Andrea Paul as General Counsel and Corporate Secretary

NEW YORK and SAN DIEGO, June 27, 2022 (GLOBE NEWSWIRE) -- Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company...

ZNTL : 10.98 (-6.67%)
Zentalis Pharmaceuticals Appoints Andrea Paul as General Counsel and Corporate Secretary

NEW YORK and SAN DIEGO, June 27, 2022 (GLOBE NEWSWIRE) -- Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company...

ZNTL : 10.98 (-6.67%)
Zentalis Pharmaceuticals Promotes Cofounder Cam Gallagher to President

NEW YORK and SAN DIEGO, May 31, 2022 (GLOBE NEWSWIRE) -- Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company...

ZNTL : 10.98 (-6.67%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Sell with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is in highly oversold territory. Beware of a trend reversal.

See More Share

Business Summary

Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. It is focused on discovering and developing small molecule therapeutics targeting cancers. The company's lead programs consist of ZN-c5, an oral selective estrogen receptor degrader for estrogen-receptor-positive, HER2-negative...

See More

Key Turning Points

3rd Resistance Point 12.27
2nd Resistance Point 11.77
1st Resistance Point 11.38
Last Price 10.98
1st Support Level 10.49
2nd Support Level 10.00
3rd Support Level 9.60

See More

52-Week High 31.46
Fibonacci 61.8% 23.09
Fibonacci 50% 20.51
Fibonacci 38.2% 17.93
Last Price 10.98
52-Week Low 9.56

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar